Results 101 to 110 of about 1,590 (205)
Dermatologic Toxicities Associated With Novel Pan‐RAS/RAF Inhibitors
ABSTRACT Background The mitogen‐activated protein kinase (MAPK) pathway plays a key role in cell‐cycle regulation and tumor progression in cancer. Dermatologic toxicities (DTs) to newer pan‐RAS (RMC‐6236) and pan‐RAF (LXH254/naporafenib) inhibitors are emerging.
Lin J. He +11 more
wiley +1 more source
Cytology‐First Diagnostic Workflow for Melanoma of Unknown Primary With Molecular Profiling
Cytology‑first diagnostic workflow for melanoma of unknown primary. Fine‑needle aspiration of an enlarged lymph node enables rapid cytologic evaluation and immunocytochemical confirmation of melanocytic lineage (SOX10). This early cytologic diagnosis facilitates timely surgical excision and comprehensive genomic profiling, supporting integrated ...
Hong Yu +3 more
wiley +1 more source
Summary Background and objectives Pruritus is a frequent cutaneous immune‐related adverse event (irAE) associated with immune checkpoint inhibitors (ICI), impacting patients' quality of life. This study investigates the incidence, severity and management of pruritus in melanoma patients treated with ICI.
Andrea Roggo +6 more
wiley +1 more source
Targeting the microbiota‐miRNA‐protease axis: A new therapeutic avenue in melanoma
Modulation of extracellular matrix (ECM) turnover is central to melanoma progression and metastasis, driven largely by ECM proteases. This review highlights the epigenetic regulation of ECM proteases by microRNAs and their roles in melanoma growth, invasion, and immune modulation.
Elias N. Katsoulieris +2 more
wiley +1 more source
This study assessed the 2022 WHO classification for predicting RAIR disease in thyroid carcinomas, comparing it to older classifications. In a retrospective study of 253 cases, we found the 2022 classification more effective, especially by identifying high‐grade carcinomas and tumour necrosis as critical predictive factors.
Elise André +10 more
wiley +1 more source
c‐Met protein overexpression can be assessed before or after treatment in patients with non‐squamous NSCLC since most patients maintain a consistent c‐Met status. However, as targeted therapies may elevate c‐Met overexpression, retesting may be necessary for subsets of patients.
Alexis B Cortot +14 more
wiley +1 more source
GBASCs are MMRp tumours, exhibiting minimal HER2 overexpression and elevated PD‐L1 expression compared to adenocarcinomas. Especially in metastatic and TP53‐wild type tumours, GBASCs can express CLDN18, albeit limited to the glandular component. Their genomic profile resembles that of adenocarcinomas with an enrichment in alterations on PIK3CA, PTEN ...
Jessica Gasparello +20 more
wiley +1 more source

